Study of COYA 302 for the Treatment of ALS
← catalyst calendarNCT07161999 · readout ≤ 164 d
Sponsored by Coya Therapeutics (industry) · COYA — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
120estimated
Sites
25
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-01 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
- Drug: COYA 302 — also filed as LD rhIL-2 and CTLA-4 Ig
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFThe change in disease progression as measured by the Revised ALS Functional Rating Scale (ALSFRS-R)
measured Baseline to Week 24
Permalink · COYA's whole pipeline · Catalyst calendar · Every registered study · What changed